npj Breast Cancer

Papers
(The median citation count of npj Breast Cancer is 5. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-01-01 to 2026-01-01.)
ArticleCitations
Author Correction: Characterization and spatial distribution of infiltrating lymphocytes in medullary, and lymphocyte-predominant triple negative breast cancers557
Discerning the impact of ctDNA detection on patient decision-making in early-stage breast cancer270
Race-related host and microbe transcriptomic signatures in triple-negative breast cancer178
Biological correlates associated with high-risk breast cancer patients identified using a computational method125
PAM50 subtyping and ROR score add long-term prognostic information in premenopausal breast cancer patients102
Intrinsic RB activation induces tumoral and stromal anti-tumor responses that limit triple-negative breast cancer100
Utilizing cell-free DNA to predict risk of developing brain metastases in patients with metastatic breast cancer98
HER2DX ERBB2 mRNA score in first-line advanced HER2-positive breast cancer treated with chemotherapy, trastuzumab, and pertuzumab97
Evolving incidence patterns for locally advanced operable breast cancer by receptor status: SEER 2010–202194
C/EBPβ isoform-specific regulation of migration and invasion in triple-negative breast cancer cells87
PARG inhibition suppresses breast cancer progression and potentiates immunoresponse through MTDH degradation mediated by E3 ligase ITCH-dependent ubiquitination81
Incidence of brain metastases in patients with early HER2-positive breast cancer receiving neoadjuvant chemotherapy with trastuzumab and pertuzumab79
Immunotherapy for early triple negative breast cancer: research agenda for the next decade74
GATA3 and markers of epithelial-mesenchymal transition predict long-term benefit from tamoxifen in ER-positive breast cancer66
HER2-low-positive breast cancer: evolution from primary tumor to residual disease after neoadjuvant treatment65
Effects of socioeconomic status and race on survival and treatment in metastatic breast cancer60
International survey on invasive lobular breast cancer identifies priority research questions59
Immunotherapy in triple negative breast cancer: beyond checkpoint inhibitors59
Biomarkers of palbociclib response in hormone receptor-positive advanced breast cancer from the PARSIFAL trial58
Comparative transcriptional analyses of preclinical models and patient samples reveal MYC and RELA driven expression patterns that define the molecular landscape of IBC56
Breastfeeding attributable fraction of triple negative breast cancer in the US54
A pragmatic, multicenter, randomized trial comparing morning versus evening dosing of adjuvant endocrine therapy (REaCT-CHRONO Study)54
Mutual exclusivity of ESR1 and TP53 mutations in endocrine resistant metastatic breast cancer53
Loss of the extracellular matrix glycoprotein EMILIN1 accelerates Δ16HER2-driven breast cancer initiation in mice53
Inhibition of CXorf56 promotes PARP inhibitor-induced cytotoxicity in triple-negative breast cancer50
Automated mitotic spindle hotspot counts are highly associated with clinical outcomes in systemically untreated early-stage triple-negative breast cancer47
Temporal evolution of breast cancer brain metastases treatments and outcomes43
Insights from a multi-institutional registry show duration of endocrine treatment for DCIS impacts second events43
The search for CDK4/6 inhibitor biomarkers has been hampered by inappropriate proliferation assays43
Estrogen receptor inhibition mediates radiosensitization of ER-positive breast cancer models42
Brain radiotherapy, tremelimumab-mediated CTLA-4-directed blockade +/− trastuzumab in patients with breast cancer brain metastases41
International research to address the challenges of metastatic breast cancer: the AURORA Program (BIG 14-01)40
Antibody-drug conjugates for treating early-stage breast cancer: current use, anticipated evolutions39
Clinical outcome and proportion of hereditary cancer genes gPV in TNBC: the HEaRTBeat study37
Survival outcomes after omission of surgery for ductal carcinoma in situ36
Perturbation and stability of PAM50 subtyping in population-based primary invasive breast cancer36
Deep learning radiomics based prediction of axillary lymph node metastasis in breast cancer35
Circulating tumor DNA validity and potential uses in metastatic breast cancer35
Single-cell transcriptomics reveals biomarker heterogeneity linked to CDK4/6 Inhibitor resistance in breast cancer cell lines35
Baseline gut microbiome alpha diversity predicts chemotherapy-induced gastrointestinal symptoms in patients with breast cancer34
Gene expression signature for predicting homologous recombination deficiency in triple-negative breast cancer33
PREDICT underestimates survival of patients with HER2-positive early-stage breast cancer33
Circulating tumour mutation detection in triple-negative breast cancer as an adjunct to tissue response assessment33
Understanding metastasis mixed-treatment responses through genomic analyses31
Cancer risk assessment of premalignant breast tissues from patients with BRCA mutations by genome profiling31
Effects of pregnancy on breast cancer immunology: immune biomarker and TIL quantification31
Is conservative management of ductal carcinoma in situ risky?31
Ductal keratin 15+ luminal progenitors in normal breast exhibit a basal-like breast cancer transcriptomic signature30
Kataegis in clinical and molecular subgroups of primary breast cancer30
Inflammatory cytokines and distant recurrence in HER2-negative early breast cancer30
Breast cancer clinical trial participation among diverse patients at a comprehensive cancer center30
Author Correction: Combining the AKT inhibitor capivasertib and SERD fulvestrant is effective in palbociclib-resistant ER+ breast cancer preclinical models30
Discovery of a novel small molecule degrader of wild type and mutant estrogen receptors using DNA encoded libraries29
Author Correction: Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer28
ZNF92, an unexplored transcription factor with remarkably distinct breast cancer over-expression associated with prognosis and cell-of-origin27
Prognostic impact of tumor-infiltrating lymphocytes in HER2+ metastatic breast cancer receiving first-line treatment27
Validation and real-world clinical application of an artificial intelligence algorithm for breast cancer detection in biopsies27
Trends in contralateral breast cancer and contralateral prophylactic mastectomy from 2009 to 201626
Computational pathology improves risk stratification of a multi-gene assay for early stage ER+ breast cancer25
Rapid autopsies to enhance metastatic research: the UPTIDER post-mortem tissue donation program25
GRHL2 motif is associated with intratumor heterogeneity of cis-regulatory elements in luminal breast cancer25
Clinicopathological characteristics and eligibility for adjuvant olaparib of germline BRCA1/2 mutation carriers with HER2-negative early breast cancer24
Large language model (ChatGPT) as a support tool for breast tumor board24
ERα-LBD, an isoform of estrogen receptor alpha, promotes breast cancer proliferation and endocrine resistance24
Real-world outcomes of early-stage HER2-positive breast cancer patients treated with adjuvant paclitaxel and trastuzumab23
Cardiac outcomes of subjects on adjuvant trastuzumab emtansine vs paclitaxel in combination with trastuzumab for stage I HER2-positive breast cancer (ATEMPT) study (TBCRC033): a randomized controlled 23
A systematic review of determinants of breast cancer risk among women with benign breast disease23
Palbociclib and letrozole for hormone receptor-positive HER2-negative breast cancer with residual disease after neoadjuvant chemotherapy23
PIK3CA co-occurring mutations and copy-number gain in hormone receptor positive and HER2 negative breast cancer23
Cook and Move for Your Life, an eHealth intervention for women with breast cancer22
Effect of cross-platform gene-expression, computational methods on breast cancer subtyping in PALOMA-2 and PALLET studies22
Clinicopathological and molecular characterization of inflammatory breast cancer, the prospective INFLAME registry study22
Author Correction: Combining the AKT inhibitor capivasertib and SERD fulvestrant is effective in palbociclib-resistant ER+ breast cancer preclinical models22
Benefit of systemic therapy in MINDACT patients with small, ER-positive, HER2-negative breast cancers21
The 21-gene recurrence score in early non-ductal breast cancer: a National Cancer Database analysis21
Early tumor volume reduction by breast DCE MRI predicts pathologic complete response to neoadjuvant therapy in triple negative breast cancer21
Prognostic value of structural variants in early breast cancer patients21
Phase 1b study of berzosertib and cisplatin in patients with advanced triple-negative breast cancer21
Real-world ANASTASE study of atezolizumab+nab-paclitaxel as first-line treatment of PD-L1-positive metastatic triple-negative breast cancer21
Predicting short- to long-term breast cancer risk from longitudinal mammographic screening history20
Plasma assay of methylated DNA markers detects recurrent metastatic breast cancer20
Interrogating breast cancer heterogeneity using single and pooled circulating tumor cell analysis20
Molecular signatures of in situ to invasive progression for basal-like breast cancers: An integrated mouse model and human DCIS study19
Evaluating mammographic density′s contribution to improve a breast cancer risk model with questionnaire-based and polygenic factors19
Dose dense versus 3 weekly AC during neoadjuvant chemoimmunotherapy for triple negative breast cancer19
Increased trunk fat is associated with altered gene expression in breast tissue of normal weight women19
Author Correction: Advancing equitable access to innovation in breast cancer19
CDK4/6i-treated HR+/HER2- breast cancer tumors show higher ESR1 mutation prevalence and more altered genomic landscape19
SIMD: Synergistic integration mutualistic platform based on single-cell and proteotranscriptomics for drug repositioning19
Therapeutic and immunomodulatory potential of pazopanib in malignant phyllodes tumor19
MRI background parenchymal enhancement, breast density and breast cancer risk factors: A cross-sectional study in pre- and post-menopausal women19
A pilot study incorporating HER2-directed dendritic cells into neoadjuvant therapy of early stage HER2+ER- breast cancer19
Author Correction: Personalized mutation tracking in circulating-tumor DNA predicts recurrence in patients with high-risk early breast cancer18
Integration of clinical features and deep learning on pathology for the prediction of breast cancer recurrence assays and risk of recurrence18
Prognostic significance of RNA-based TP53 pathway function among estrogen receptor positive and negative breast cancer cases18
Plasma C-peptide mammographic features and risk of breast cancer18
Personalized neoadjuvant strategy using 70-gene assay to increase breast-conserving surgery in ER+/HER2– breast cancer18
Changes in intestinal microbiota in postmenopausal oestrogen receptor-positive breast cancer patients treated with (neo)adjuvant chemotherapy18
Window-of-opportunity trials to screen effective agents and optimize dose in breast cancer prevention18
Proteogenomic characterization of invasive breast tumors in young women18
ERα/PR crosstalk is altered in the context of the ERα Y537S mutation and contributes to endocrine therapy-resistant tumor proliferation18
Second breast cancer: recurrence score results, clinicopathologic characteristics, adjuvant treatments, and outcomes—exploratory analysis of the Clalit registry18
Racial discrimination among women seeking breast cancer care17
Gene signatures in patients with early breast cancer and relapse despite pathologic complete response17
Liquid biopsy for brain metastases and leptomeningeal disease in patients with breast cancer17
Baseline cell cycle and immune profiles indicate CDK4/6 inhibitor response in metastatic HR + /HER2- breast cancer17
Assessment of MRI to estimate metastatic dissemination risk and prometastatic effects of chemotherapy17
Molecular characterization of pregnancy-associated breast cancer and insights on timing from GEICAM-EMBARCAM study17
The different prognostic significance of polysialic acid and CD56 expression in tumor cells and lymphocytes identified in breast cancer16
Post-diagnosis weight trajectories and mortality among women with breast cancer16
Prevalence, clinicopathologic features and long-term overall survival of early breast cancer patients eligible for adjuvant abemaciclib and/or ribociclib16
Development and validation of a clinical breast cancer tool for accurate prediction of recurrence16
Association between ancestry and tumor somatic mutations in a large national cohort of women with breast cancer16
Genomic landscape of breast cancer in elderly patients16
Predictors of response to CDK4/6i retrial after prior CDK4/6i failure in ER+ metastatic breast cancer16
Novel treatment strategies and key research priorities for patients with breast cancer and central nervous system (CNS) metastases16
Clinical outcomes of de novo metastatic HER2-positive inflammatory breast cancer16
Immunologically “cold” triple negative breast cancers engraft at a higher rate in patient derived xenografts15
Author Correction: Phase III study of HR-positive/HER2-negative/lymph node-positive breast cancer non-responsive to primary chemotherapy: a randomized trial15
Susceptibility gene mutations in germline and tumors of patients with HER2-negative advanced breast cancer15
Incidence and impact of brain metastasis in patients with hereditary BRCA1 or BRCA2 mutated invasive breast cancer15
RNA sequencing-based single sample predictors of molecular subtype and risk of recurrence for clinical assessment of early-stage breast cancer15
Artificial intelligence in breast pathology – dawn of a new era15
Alternative trastuzumab dosing strategies in HER2-positive early breast cancer are associated with patient out-of-pocket savings15
Author Correction: Defining features of hereditary lobular breast cancer due to CDH1 with magnetic resonance imaging and tumor characteristics15
Advancing equitable access to innovation in breast cancer15
Validation of minimal risk of recurrence classification by the Breast Cancer Index in early stage breast cancer15
Estrogen receptor beta repurposes EZH2 to suppress oncogenic NFκB/p65 signaling in triple negative breast cancer15
Predictors of success in establishing orthotopic patient-derived xenograft models of triple negative breast cancer15
Stromal fibroblastic mutant Trp53 promotes mammary tumor development via enhanced secretion of paracrine factors14
Genomic landscapes of breast cancer in African populations: a systematic review14
The prognostic value and immune microenvironment association of AR in HER2+ nonmetastatic breast cancer14
Tumor infiltrating lymphocyte stratification of prognostic staging of early-stage triple negative breast cancer14
MammOnc-DB, an integrative breast cancer data analysis platform for target discovery14
Adaptive immune signature in HER2-positive breast cancer in NCCTG (Alliance) N9831 and NeoALTTO trials14
Predicting early breast cancer recurrence from histopathological images in the Carolina Breast Cancer Study14
Safety analyses from the phase 3 ASCENT trial of sacituzumab govitecan in metastatic triple-negative breast cancer14
Author Correction: Clinical impact of drug-drug interactions on abemaciclib in the real-world experience of AB-ITALY study14
Enabling sensitive and precise detection of ctDNA through somatic copy number aberrations in breast cancer13
Proof-of-concept study linking ex vivo sensitivity testing to neoadjuvant anthracycline-based chemotherapy response in breast cancer patients13
An updated PREDICT breast cancer prognostic model including the benefits and harms of radiotherapy13
PROCURE European consensus on breast cancer multigene signatures in early breast cancer management13
Computerized cognitive training improves cognitive function in primary breast cancer survivors13
Predictors of response to neoadjuvant chemo-immunotherapy in metaplastic triple-negative breast cancer13
An emerging generation of endocrine therapies in breast cancer: a clinical perspective13
Author Correction: Primary endocrine resistance of ER+ breast cancer with ESR1 mutations interrogated by droplet digital PCR13
Mcam stabilizes a luminal progenitor-like breast cancer cell state via Ck2 control and Src/Akt/Stat3 attenuation13
De-escalation in breast cancer surgery13
Co-targeting of metabolism using dietary and pharmacologic approaches reduces breast cancer metastatic burden13
Clinical-pathologic characteristics and response to neoadjuvant chemotherapy in triple-negative low Ki-67 proliferation (TNLP) breast cancers13
The impact of age and nodal status on variations in oncotype DX testing and adjuvant treatment13
Pathologic complete response and survival after neoadjuvant chemotherapy in cT1-T2/N0 HER2+ breast cancer13
Spatial proximity of CD8+ T cells to tumor cells predicts neoadjuvant therapy efficacy in breast cancer13
Basal-like HR + /HER2- breast cancers show higher tumor-infiltrating lymphocytes and immune signatures with potential therapeutic implications13
High-dimensional immune cell profiling of cerebrospinal fluid from patients with metastatic breast cancer and leptomeningeal disease13
Breast cancer survivors’ opinion on personalizing endocrine therapy and developing informative tools12
Automated quantification of levels of breast terminal duct lobular (TDLU) involution using deep learning12
Bridging the gap: ctDNA, genomics, and equity in breast cancer care12
Multi-center study on predicting breast cancer lymph node status from core needle biopsy specimens using multi-modal and multi-instance deep learning12
Mortality after second malignancy in breast cancer survivors compared to a first primary cancer: a nationwide longitudinal cohort study12
A biomarker of aging, p16, predicts peripheral neuropathy in women receiving adjuvant taxanes for breast cancer12
Immunoarchitectural patterns as potential prognostic factors for invasive ductal breast cancer12
Spatial interplay of tissue hypoxia and T-cell regulation in ductal carcinoma in situ11
Molecular differences between younger versus older ER-positive and HER2-negative breast cancers11
Tumor-infiltrating lymphocytes in HER2-positive breast cancer treated with neoadjuvant chemotherapy and dual HER2-blockade11
Associations with response to Poly(ADP-ribose) Polymerase (PARP) inhibitors in patients with metastatic breast cancer11
Personalized ctDNA detection and genomic profiling in the NeoRHEA Study11
Ruxolitinib and exemestane for estrogen receptor positive, aromatase inhibitor resistant advanced breast cancer11
Racial and demographic disparities in glp-1ra use among breast cancer patients with Type 2 Diabetes11
Evaluation of multigene assays as predictors for response to neoadjuvant chemotherapy in early-stage breast cancer patients11
Pak1 pathway hyper-activation mediates resistance to endocrine therapy and CDK4/6 inhibitors in ER+ breast cancer11
Illuminating the clinicopathological and genomic landscape of HER2-null, ultralow, and low breast cancers: insights into diagnostic discordance between biopsy and surgical excision11
Apatinib plus vinorelbine versus vinorelbine for metastatic triple-negative breast cancer who failed first/second-line treatment: the NAN trial11
The deubiquitinating enzyme USP4 regulates BRCA1 stability and function11
Reply to: PREDICT underestimates survival of patients with HER2-positive early-stage breast cancer10
HER2-low and ultralow expression of invasive breast carcinoma: clinicopathological features and immunohistochemical consistency analysis10
Qualification of a multiplexed tissue imaging assay and detection of novel patterns of HER2 heterogeneity in breast cancer10
Solid-basaloid variant of adenoid cystic carcinoma of the breast with near complete response to neoadjuvant chemotherapy10
Effects of acute exercise on inflammatory and metabolic biomarkers in women: a randomized controlled trial10
Author Correction: Upregulation of lipid metabolism genes in the breast prior to cancer diagnosis10
Pyrotinib and trastuzumab plus palbociclib and fulvestrant in HR+/HER2+ breast cancer patients with brain metastasis10
Germline variants of the POLH and RAD51 genes are candidate variants associated with risk of hormone receptor-negative young-onset breast cancer10
Bone mineral density in women newly diagnosed with breast cancer: a prospective cohort study10
The pleiotropic roles of non-hormonal receptor basigin and regulatory microRNAs in breast cancer10
Improving the odds together: a framework for breast cancer research scientists to include patient advocates in their research10
Optimal adjuvant therapy in older (≥70 years of age) women with low-risk early-stage breast cancer9
Endoxifen downregulates AKT phosphorylation through protein kinase C beta 1 inhibition in ERα+ breast cancer9
SPP1+ macrophages in HR+ breast cancer are associated with tumor-infiltrating lymphocytes9
High prevalence of somatic PIK3CA and TP53 pathogenic variants in the normal mammary gland tissue of sporadic breast cancer patients revealed by duplex sequencing9
High GPER expression in triple-negative breast cancer is linked to pro-metastatic pathways and predicts poor patient outcomes9
Invasive disease-free survival and brain metastasis rates in patients treated with neoadjuvant chemotherapy with trastuzumab and pertuzumab9
Elacestrant demonstrates strong anti-estrogenic activity in PDX models of estrogen-receptor positive endocrine-resistant and fulvestrant-resistant breast cancer9
Adjuvant endocrine therapy with cyclin-dependent kinase 4/6 inhibitor, ribociclib, for localized hormone receptor-positive/HER2– breast cancer (LEADER)9
Cancer cell-monocyte co-culture spheroids recapitulate pro-tumorigenic, immunosuppressive, and drug-resistant microenvironments in brain metastatic breast cancer9
Understanding the association between body mass index and chemotherapy dose reductions in women treated for stage I-IIIA breast cancer9
Image analysis-based tumor infiltrating lymphocytes measurement predicts breast cancer pathologic complete response in SWOG S0800 neoadjuvant chemotherapy trial9
A 20-feature radiomic signature of triple-negative breast cancer identifies patients at high risk of death9
Allostatic load as a predictor of postoperative complications in patients with breast cancer9
Incidence of HER2-expressing brain metastases in patients with HER2-null breast cancer: a matched case analysis9
MUC1-C dependency in drug resistant HR+/HER2− breast cancer identifies a new target for antibody-drug conjugate treatment8
Endoplasmic reticulum stress inhibits AR expression via the PERK/eIF2α/ATF4 pathway in luminal androgen receptor triple-negative breast cancer and prostate cancer8
Enhanced bioluminescence imaging of tumor cells surviving chemotherapy in a murine model of triple-negative breast cancer8
CBD-oil as a potential solution in case of severe tamoxifen-related side effects8
Real-world study of overall survival with palbociclib plus aromatase inhibitor in HR+/HER2− metastatic breast cancer8
Circulating genomic landscape following cyclin-dependent kinase 4/6 inhibitors exposure in HR + /HER2− metastatic breast cancer: a retrospective multi-institutional Consortium analysis8
Racial and ethnic disparities in neoadjuvant chemotherapy patterns and outcomes in early-stage HER2-positive breast cancer8
Crystal structure of active CDK4-cyclin D and mechanistic basis for abemaciclib efficacy8
Effects of RARα ligand binding domain mutations on breast fibroepithelial tumor function and signaling8
Modeling tumor relapse using proliferation tracing and ablation transgenic mouse8
Author Correction: Development and characterisation of a novel 3D in vitro model of obesity-associated breast cancer as a tool for drug testing8
Genomic analysis of advanced breast cancer tumors from talazoparib-treated gBRCA1/2mut carriers in the ABRAZO study8
Immunotherapy in breast cancer: an overview of current strategies and perspectives7
Author Correction: Real-world ANASTASE study of atezolizumab+nab-paclitaxel as first-line treatment of PD-L1-positive metastatic triple-negative breast cancer7
The impact of reproductive factors on DNA methylation-based telomere length in healthy breast tissue7
Predicting pathologic ≥N2 disease in women with breast cancer7
Disease characterization in liquid biopsy from HER2-mutated, non-amplified metastatic breast cancer patients treated with neratinib7
Clinical outcomes in estrogen receptor-positive early-stage breast cancer patients with Recurrence Score 26-30: observational real-world cohort study7
Calcifications in triple-negative breast cancer: Molecular features and treatment strategies7
LINC00355 regulates p27KIP expression by binding to MENIN to induce proliferation in late-stage relapse breast cancer7
Tamoxifen or aromatase inhibitors with ovarian function suppression in pre-menopausal stage I-III lobular breast cancer7
Increased blood draws for ultrasensitive ctDNA and CTCs detection in early breast cancer patients7
Author Correction: Subgroup analyses from the phase 3 ASCENT study of sacituzumab govitecan in metastatic triple-negative breast cancer7
Prognostic and molecular multi-platform analysis of CALGB 40603 (Alliance) and public triple-negative breast cancer datasets7
Pure estrogen receptor antagonists potentiate capecitabine activity in ESR1-mutant breast cancer7
Breast cancer Intraoperative Margin Assessment using specimen PET-CT (BIMAP)7
Adjuvant S-1 plus endocrine therapy for ER-positive, HER2-negative, primary breast cancer: post-POTENT trial prognostic survey6
Impact of a randomized weight loss trial on breast tissue markers in breast cancer survivors6
Tractable mouse TNBC models capture the heterogeneous tumor immune microenvironment and adaptation to PD-L1 blockade6
CDK2 inhibition enhances CDK4/6 inhibitor antitumor activity in comprehensive breast cancer PDX model screen6
Gedatolisib shows superior potency and efficacy versus single-node PI3K/AKT/mTOR inhibitors in breast cancer models6
Circulating tumor cells in early lobular versus ductal breast cancer and their associations with prognosis6
Association between tumor-infiltrating lymphocytes and survival in patients with metastatic breast cancer receiving first-line chemotherapy: analysis of CALGB 405026
Clonal heterogeneity in ER+ breast cancer reveals the proteasome and PKC as potential therapeutic targets6
Impact of body mass index in therapeutic response for HER2 positive breast cancer treated with neoadjuvant targeted therapy: a multi-center study and meta-analysis6
Personalized ctDNA monitoring in metastatic HR+/HER2− breast cancer patients during endocrine and CDK4/6 inhibitor therapy6
Accessible model predicts response in hormone receptor positive HER2 negative breast cancer receiving neoadjuvant chemotherapy6
NR4A3 potentials M1-like macrophage polarization to facilitate anti-tumor immune responses in breast cancer6
Dose dense doxorubicin plus cyclophosphamide in a modified KEYNOTE522 regimen for triple negative breast cancer6
Optimizing clinical monitoring and management guidelines for capivasertib in HR-positive/HER2-negative advanced breast cancer: expert opinion6
HER2-low breast cancer is immune-cold: insights into tumor-infiltrating immune cells and implications for immunotherapy6
Results from the randomized KEYNOTE-355 study of pembrolizumab plus chemotherapy for Asian patients with advanced TNBC6
Antibody–drug conjugates in breast cancer: mechanisms of resistance and future therapeutic perspectives6
Magnetic resonance imaging insights from active surveillance of women with ductal carcinoma in situ6
Clinico-pathological predictors of radiologic complete response to first-line anti-HER2 therapy in metastatic breast cancer5
PI3K/AKT signaling activates HIF1α to modulate the biological effects of invasive breast cancer with microcalcification5
HBXIP induces anoikis resistance by forming a reciprocal feedback loop with Nrf2 to maintain redox homeostasis and stabilize Prdx1 in breast cancer5
Sacituzumab govitecan as second-line treatment for metastatic triple-negative breast cancer—phase 3 ASCENT study subanalysis5
Clinical relevance of pathogenic germline variants in mismatch repair genes in Chinese breast cancer patients5
Reversion of breast epithelial polarity alterations caused by obesity5
Clinical and genetic predictors of persistent chemotherapy-induced alopecia despite scalp cooling in breast cancer5
0.67160701751709